See more : Blue Star Gold Corp. (BAU.V) Income Statement Analysis – Financial Results
Complete financial analysis of Tevogen Bio Holdings Inc. (TVGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tevogen Bio Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tekfen Holding Anonim Sirketi (TKFHY) Income Statement Analysis – Financial Results
- Japan Airport Terminal Co., Ltd. (JAIRF) Income Statement Analysis – Financial Results
- Rajdarshan Industries Limited (ARENTERP.NS) Income Statement Analysis – Financial Results
- Churchill Capital Corp V (CCV-UN) Income Statement Analysis – Financial Results
- Franklin Street Properties Corp. (FSP) Income Statement Analysis – Financial Results
Tevogen Bio Holdings Inc. (TVGN)
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 5.77M | 2.96M |
| General & Administrative | 2.27M | 953.08K | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 2.27M | 953.08K | 1.66M |
| Other Expenses | 0.00 | -7.38M | -10.38M |
| Operating Expenses | 2.27M | 953.08K | 4.62M |
| Cost & Expenses | 2.27M | 953.08K | 4.62M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 256.03K | 0.00 | 598.50K |
| Depreciation & Amortization | 197.55K | 230.82K | 9.38K |
| EBITDA | 188.71K | -953.08K | -28.75K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.84K | -13.72M | -4.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -58.48K | 4.42M | -15.59M |
| Income Before Tax | -67.33K | 4.41M | -15.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -230.82K | -9.78M |
| Net Income | -67.33K | 4.41M | -15.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.04 | -0.13 |
| EPS Diluted | 0.00 | 0.04 | -0.13 |
| Weighted Avg Shares Out | 165.42M | 120.00M | 120.00M |
| Weighted Avg Shares Out (Dil) | 165.42M | 120.00M | 120.00M |
Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame
WARREN, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, CEO of Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and...
Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy
WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced addition responsibilities...
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value
WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to...
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model
WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results...
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. Tevogen's success would not be possible without its passionate team united by a...
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials
Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. Tevogen's success would not be possible without its passionate team united by a...
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement...
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920
WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial...
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support
WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce...
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
WARREN, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shares details of its...
Source: https://incomestatements.info
Category: Stock Reports